限制性Vβ可用于T细胞淋巴瘤白血病期的证据  

Evidence for restricted Vβ usage in the leukemic phase of cutaneous T cell lymphoma

作　　者：Vonderheid E.C. Boselli C.M. Conroy M. 张宪旗 

机构地区：[1]Dr.550 N. Broadway Building, Baltimore, MD 21205, United States

出　　处：《世界核心医学期刊文摘（皮肤病学分册）》2005年第8期39-39,共1页Digest of the World Core Medical JOurnals:Dermatology

摘　　要：Antibodies directed against the β chain of the T cell receptor (anti- Vβ antibodies) are useful to identify the Vβ repertoire of T cells in various diseases and to quantify numbers of Vβ - bearing T cells. The goals of this study were to identify Vβ + cases of leukemic phase cutaneous T cell lymphoma (CTCL) and to compare the percentage of positive calls with other measures of blood tumor burden, i.e., lymphocyte subsets with a CD4+ CD7- and CD4+ CD26- phenotype and Se′ zary cell counts. Thirty- three of 49 (67% ) cases of leukemic CTCL reacted with an anti- Vβ antibody. When combined with reports from the literature, the frequency of Vβ 5 (probably Vβ 5.1) usage was relatively high when compared with Vβ 2that is also frequently expressed by normal CD4+ T cells. The percentage of Vβ + cells correlated to the percentage of CD4+ CD7- and CD4+ CD26- cells for cases in which the neoplastic cells were deficient in expression of CD7 and CD26, respectively, but not the Se′ zary cell count. We hypothesize that the increased Vβ 5.1 usage in CTCL may be the result of depletion of Vβ 2 and other Vβ - bearing T cells by staphylococcal superantigens prior to neoplastic transformation, resulting in a relative increase in the frequency of Vβ 5.1 usage in CTCL.Antibodies directed against the β chain of the T cell receptor (anti- Vβ antibodies) are useful to identify the Vβ repertoire of T cells in various diseases and to quantify numbers of Vβ - bearing T cells. The goals of this study were to identify Vβ + cases of leukemic phase cutaneous T cell lymphoma (CTCL) and to compare the percentage of positive calls with other measures of blood tumor burden, i.e., lymphocyte subsets with a CD4+ CD7- and CD4+ CD26- phenotype and Se′ zary cell counts. Thirty- three of 49 (67% ) cases of leukemic CTCL reacted with an anti- Vβ antibody. When combined with reports from the literature, the frequency of Vβ 5 (probably Vβ 5.1) usage was relatively high when compared with Vβ 2that is also frequently expressed by normal CD4+ T cells. The percentage of Vβ + cells correlated to the percentage of CD4+ CD7- and CD4+ CD26- cells for cases in which the neoplastic cells were deficient in expression of CD7 and CD26, respectively, but not the Se′ zary cell count. We hypothesize that the increased Vβ 5.1 usage in CTCL may be the result of depletion of Vβ 2 and other Vβ - bearing T cells by staphylococcal superantigens prior to neoplastic transformation, resulting in a relative increase in the frequency of Vβ 5.1 usage in CTCL.

关 键 词：淋巴瘤白血病 T细胞淋巴瘤 细胞亚群 肿瘤负荷 计数检测 肿瘤形成 阳性反应 抗原刺激 Β链 文献资料 

分 类 号：R739.5[医药卫生—肿瘤]